NUVL
Price
$106.90
Change
+$1.94 (+1.85%)
Updated
Dec 3 closing price
Capitalization
8.3B
90 days until earnings call
Intraday BUY SELL Signals
PHVS
Price
$29.36
Change
+$5.24 (+21.72%)
Updated
Dec 3 closing price
Capitalization
1.91B
131 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NUVL vs PHVS

Header iconNUVL vs PHVS Comparison
Open Charts NUVL vs PHVSBanner chart's image
Nuvalent
Price$106.90
Change+$1.94 (+1.85%)
Volume$450.52K
Capitalization8.3B
Pharvaris
Price$29.36
Change+$5.24 (+21.72%)
Volume$3.54M
Capitalization1.91B
NUVL vs PHVS Comparison Chart in %
NUVL
Daily Signal:
Gain/Loss:
PHVS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NUVL vs. PHVS commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Hold and PHVS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (NUVL: $104.96 vs. PHVS: $24.18)
Brand notoriety: NUVL and PHVS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 26% vs. PHVS: 62%
Market capitalization -- NUVL: $8.3B vs. PHVS: $1.91B
NUVL [@Biotechnology] is valued at $8.3B. PHVS’s [@Biotechnology] market capitalization is $1.91B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whilePHVS’s FA Score has 0 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • PHVS’s FA Score: 0 green, 5 red.
According to our system of comparison, both NUVL and PHVS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 4 TA indicator(s) are bullish while PHVS’s TA Score has 6 bullish TA indicator(s).

  • NUVL’s TA Score: 4 bullish, 4 bearish.
  • PHVS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PHVS is a better buy in the short-term than NUVL.

Price Growth

NUVL (@Biotechnology) experienced а -4.46% price change this week, while PHVS (@Biotechnology) price change was -4.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

NUVL is expected to report earnings on Mar 04, 2026.

PHVS is expected to report earnings on Apr 14, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($8.3B) has a higher market cap than PHVS($1.91B). NUVL YTD gains are higher at: 34.083 vs. PHVS (26.135). PHVS has higher annual earnings (EBITDA): -165.21M vs. NUVL (-362.01M). NUVL has more cash in the bank: 1.01B vs. PHVS (200M). NUVL (0) and PHVS (0) have equivalent revenues.
NUVLPHVSNUVL / PHVS
Capitalization8.3B1.91B435%
EBITDA-362.01M-165.21M219%
Gain YTD34.08326.135130%
P/E RatioN/AN/A-
Revenue00-
Total Cash1.01B200M503%
Total DebtN/A634K-
TECHNICAL ANALYSIS
Technical Analysis
NUVLPHVS
RSI
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 7 days ago
85%
Momentum
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 7 days ago
84%
MACD
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 7 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 7 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
82%
Advances
ODDS (%)
Bullish Trend 10 days ago
83%
Bullish Trend 7 days ago
77%
Declines
ODDS (%)
Bearish Trend 25 days ago
78%
Bearish Trend 21 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 7 days ago
84%
Aroon
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 7 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signal:
Gain/Loss:
PHVS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSAEX14.64N/A
N/A
Fidelity Series All-Sector Equity
OTPSX40.64N/A
N/A
ProFunds NASDAQ-100 Svc
VIGRX251.68N/A
N/A
Vanguard Growth Index Investor
ERSTX27.59N/A
N/A
Eaton Vance Large-Cap Value R
GCCHX24.99N/A
N/A
GMO Climate Change III

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XNCR. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
-1.37%
XNCR - NUVL
60%
Loosely correlated
-3.15%
RVMD - NUVL
59%
Loosely correlated
-0.65%
IDYA - NUVL
58%
Loosely correlated
-1.75%
XENE - NUVL
58%
Loosely correlated
-1.45%
VRDN - NUVL
56%
Loosely correlated
-3.26%
More

PHVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHVS has been loosely correlated with INKT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if PHVS jumps, then INKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHVS
1D Price
Change %
PHVS100%
-7.00%
INKT - PHVS
36%
Loosely correlated
-2.07%
NUVL - PHVS
34%
Loosely correlated
-1.37%
MGTX - PHVS
33%
Poorly correlated
-1.21%
HOWL - PHVS
31%
Poorly correlated
-6.05%
CELC - PHVS
30%
Poorly correlated
-1.01%
More